ONL Therapeutics

24 articles about ONL Therapeutics

• ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference

  2/6/2024

  ONL Therapeutics, Inc. announced that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 27 at 2:30 PM ET.

• ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society

  1/23/2024

  ONL Therapeutics, Inc. announced that David Zacks, M.D., Ph.D. and the Edna H. Perkiss will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.

• ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

  8/28/2023

  ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the completion of patient enrollment in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).

• ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

  4/12/2023

  ONL Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).

• ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial

  3/8/2023

  ONL Therapeutics, Inc. today announced it has closed on the first tranche of a $15 million Series C Preferred Stock financing round.

• ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference

  2/2/2023

  ONL Therapeutics, Inc. announced today that David Esposito, chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Monday, February 6, 2023, at 2:00 p.m. ET.

• ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research

  1/26/2023

  ONL Therapeutics, Inc. today announced that the company will share new clinical data on ONL1204 Ophthalmic Solution in the treatment of patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) at the upcoming 46th Annual Macula Society Meeting and the XXVth Biennial Meeting.

• ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer

  2/9/2022

  ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced the appointment of Sushanta Mallick, PhD, MBA, to the newly created position of Chief Development Officer.

• 

  Money on the Move: January 12 – 18

  1/19/2022

  Funds are always flowing in the life science industry. Here’s where the money’s headed this week.

• ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones

  1/13/2022

  ONL Therapeutics, Inc. today announced it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million.

• ONL Therapeutics Names Connie Chang as Chief Operating OfficerCompany expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration

  1/19/2021

  ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Connie Chang to the newly created position of chief operating officer (COO).

• 

  Biopharma Money on the Move: December 16-22

  12/23/2020

  A roundup of the latest biopharma companies scooping up cash through IPOs and financing rounds.

• ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications

  12/22/2020

  ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it closed on $46.9 million in a Series B Preferred Stock financing round. The financing included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors th

• ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204ONL Therapeutics transformed into a clinical stage biopharmaceutical company with first-in-human study

  10/23/2019

  ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient has been treated in the company’s First-in-Human trial with its lead drug candidate ONL1204

• ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

  5/18/2017

• ONL Therapeutics Strengthens Leadership With Addition To Board Of Directors And Expansion Of Operations Team

  3/29/2017

• ONL Therapeutics Receives Nearly $1.0 Million Grant From National Eye Institute For Continued Advancement Of ONL1204 Program

  3/21/2017

• ONL Therapeutics Receives Orphan Drug Designation For ONL1204 For Treatment Of Retinal Detachment From FDA

  2/11/2016

• ONL Therapeutics To Present At The 2015 Ophthalmology Innovation Summit At American Academy of Ophthalmology Annual Meeting

  10/30/2015

• ONL Therapeutics Announces Formation Of Scientific Advisory Board

  10/15/2015